$ENDP At $5.86, Is Endo International plc (NASDAQ:ENDP) A

New Post Public Reply Private Reply Replies (1) Message Board
jonny_red32
240
$ENDP At $5.86, Is Endo International plc (NASDAQ:ENDP) A Buy?



Endo International plc (NASDAQ:ENDP), a pharmaceuticals company based in Ireland, received a lot of attention from a substantial price movement on the NasdaqGS in the over the last few months, increasing to $8.86 at one point, and dropping to the lows of $5.86. This high level of volatility gives investors the opportunity to enter into the stock, and potentially buy at an artificially low price. A question to answer is whether Endo International’s current trading price of $5.86 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Endo International’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change. View our latest analysis for Endo International

What’s the opportunity in Endo International?

Great news for investors – Endo International is still trading at a fairly cheap price. My valuation model shows that the intrinsic value for the stock is $25.4, but it is currently trading at US$5.86 on the share market, meaning that there is still an opportunity to buy now. Endo International’s share price also seems relatively stable compared to the rest of the market, as indicated by its low beta. If you believe the share price should eventually reach its true value, a low beta could suggest it is unlikely to rapidly do so anytime soon, and once it’s there, it may be hard to fall back down into an attractive buying range.

What kind of growth will Endo International generate?



Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to grow by 95.30% over the next couple of years, the future seems bright for Endo International. It looks like higher cash flows is on the cards for the stock, which should feed into a higher share valuation.

What this means for you:

Are you a shareholder? Since ENDP is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as financial health to consider, which could explain the current undervaluation.

Are you a potential investor?

If you’ve been keeping an eye on ENDP for a while, now might be the time to enter the stock. Its buoyant future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy ENDP. But before you make any investment decisions, consider other factors such as the strength of its balance sheet, in order to make a well-informed buy.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Endo International. You can find everything you need to know about Endo International in the latest infographic research report. If you are no longer interested in Endo International, you can use our free platform to see my list of over 50 other stocks with a high growth potential.
Engineer by trade & Swing Trader at Heart!

Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW


CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment






Scroll down for more posts ▼

Top 10 Most Recent News Articles

Flood Insurance: Crucial for Silver Spring Owners?

Updated Category News Views 2

Flood Risk: A Reality Check for Homeowners Alright folks, let's dive into a topic that's been soaking up attention lately—flood insurance in Silver Spring, Maryland. Seems like everyone assumes they're safe from watery doom if they're standing outside those high-risk FEMA flood zones. But here's the kicker: Glenda Martinez, the big cheese at Xcella Insurance Group,...

Continue Reading
Rznomics Advances with EU Orphan Status for RZ-001

Updated Category News Views 0

RZ-001's European Success: A New Frontier Look, when a biopharmaceutical firm's RNA-editing therapy snags an Orphan Medicinal Product Designation from the European Commission, it's not just some clipboard milestone—it's a heavy-hitter move. That's exactly what Rznomics, the South Korean gene therapy player, pulled off with RZ-001. Now, we aren't just seeing paperwork...

Continue Reading
Guwahati Training Elevates Ophthalmologists: More Ready Surgeons

Updated Category News Views 4

Expanding Horizons: Training Where It's Needed The universe of cataract surgery in India saw an encouraging turn with HelpMeSee's recent initiative in Guwahati. This operation hit the sweet spot for Northeast India's ophthalmologists by bringing top-notch surgical training directly to their doorstep. Bye-bye long, costly trips to distant cities for training—this time,...

Continue Reading
Phoenix Reveals Cost-Saving Hacks for Transfer Students

Updated Category News Views 5

Making College Cost Manageable Okay, let's get real about college costs. Tuition fees got folks holding their breath tighter than a bull in a bear market. University of Phoenix ain't turning a blind eye—during National Transfer Student Week, they're shouting from the rooftops about pocket-friendly ways to snag that degree without selling your soul or flipping another...

Continue Reading
Unicycive Faces Legal Heat: Investors Eye Key Deadline

Updated Category News Views 1

What Went Wrong with Unicycive? Unicycive Therapeutics, Inc., a player in the biotech space, finds itself embroiled in a legal quagmire. A class action lawsuit is hovering over NASDAQ:UNCY, spurred by allegations of the company's slip-ups in manufacturing oversight. Investors are ticked off, understandably, as the lawsuit zeroes in on failures to resolve FDA-cited issues....

Continue Reading
Berney Flowers Rings the Bell on Fiscal Reform

Updated Category News Views 2

Berney Flowers: A Voice for Fiscal Change Oh boy, Berney Flowers sure isn't holding back. The Maryland congressional candidate is out here on Biz Talk Today TV, aiming straight at the heart of government waste and promising fiscal reform with the kind of intensity you don't see every day. Through the airwaves, he's been championing independent audits to keep those...

Continue Reading
Older Voters Dominate NY Elections: 2026 Analysis

Updated Category News Views 6

Older Voters Set to Shape New York's 2026 Election Picture this: a bustling city, the epitome of change and diversity, where the wallets of New York can be swayed by those who've seen more than half a century under their belts. The latest voter analysis tells us that New York's political landscape is leaning heavily on the shoulders of voters aged 50 and above. They...

Continue Reading
ICEYE's Wildfire Intelligence: A Game-Changer with OroraTech

Updated Category News Views 0

Wildfire Intelligence Gets a Boost from Space If you think keeping tabs on wildfires is just another task for dusty old fire towers, think again. The satellite game is changing up the field in a monumental way with ICEYE and OroraTech teaming up to bring a sharper eye to wildfire monitoring. With the integration of ICEYE’s SAR (Synthetic Aperture Radar) capabilities and...

Continue Reading
Open Point's UK Debut: AI Pioneers Stakeholder Solutions

Updated Category News Views 4

A New Era for Stakeholder Engagement in the UK The sands are shifting, folks. We're talking about Open Point stepping onto the UK's stage with its AI-powered platform that's already been turning heads elsewhere. They've got their sights set on reshaping how UK organizations handle stakeholder engagement. Why? Because the government's big on pushing through planning...

Continue Reading
Dean Tucci Fights a $43 Million CFPB Penalty

Updated Category News Views 5

Another Day, Another Court Battle Well, folks, if you thought corporate America was the only place where the numbers get wild, let me introduce you to Dean Tucci's latest legal nightmare. The man's up against a $43 million judgment from the Consumer Financial Protection Bureau (CFPB). For a business that did $2 million over three years? Yeah, you heard that right—sounds...

Continue Reading

Top 5 Most Recently Viewed Articles

CROSS Protocol Secures $10M with Innovative Public Offering

Updated Category News Views 199

CROSS Protocol Secures $10 Million in Private Token Sale CROSS Protocol, a pioneer in the blockchain gaming industry, has achieved a significant milestone by securing $10 million in a private token sale. This landmark funding effort also introduces a revolutionary equal pricing model designed to benefit all investors uniformly. Details of the Token Sale In total, CROSS...

Continue Reading
Experience the Silence: Slotozilla's New Interactive Project

Updated Category News Views 216

Introducing Slotozilla's Unique Project on Silence Slotozilla, a central platform for online gaming insights and storytelling, is excited to unveil its latest venture: "The Power of Silence." This innovative experience invites individuals to ponder the consequences of a world suddenly devoid of speech, highlighting the essential nature of communication. A World Without...

Continue Reading
Innovative Partnership to Enhance Global Drug Development Success

Updated Category News Views 219

Strategic Alliance Enhancing Drug Development Radyus Research and Eurofins CDMO Alphora have forged a strategic partnership aiming to accelerate early-stage drug development for biotech firms around the globe. With Radyus based in the U.S. and Eurofins CDMO Alphora in Canada, the collaboration seeks to harness their strengths in operational research and development. A...

Continue Reading
Insights on Women's Health: Menopause and Its Persistent Effects

Updated Category News Views 306

Understanding the Struggles Women Face After Menopause Managing health during different stages of menopause can be quite challenging for many women. Recent survey findings provide significant insight into the common symptoms and healthcare experiences associated with peri-menopause, menopause, and post-menopause. Nature's Bounty, a brand known for its commitment to...

Continue Reading
Navigating 2025's Market Trends: Winners and Losers Unpacked

Updated Category News Views 108

Unveiling the Market Dynamics of 2025 As we journey through 2025, I've taken a closer look at the market's ebb and flow, examining what I refer to as the "real report card" for the year. The findings are nothing short of intriguing. Highlighting the Market Stars Among the most notable performers in the tech sector, stocks like Coinbase (COIN) are experiencing impressive...

Continue Reading